C07K 14/16
Hiv-1
Official title: Hiv-1 {; hiv-2}
C07K14/16 (Hiv-1) appears on 171 US grants and 264 published applications in this corpus.
Search patents in C07K- Granted patents
- 171
- Published applications
- 264
- Assignees
- 162
- Inventors
- 477
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 2 |
| 2005 | 0 | 8 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 2 |
| 2009 | 7 | 2 |
| 2010 | 0 | 1 |
| 2011 | 2 | 8 |
| 2012 | 2 | 2 |
| 2013 | 1 | 12 |
| 2014 | 4 | 8 |
| 2015 | 6 | 10 |
| 2016 | 4 | 19 |
| 2017 | 11 | 8 |
| 2018 | 18 | 20 |
| 2019 | 17 | 33 |
| 2020 | 11 | 25 |
| 2021 | 21 | 32 |
| 2022 | 18 | 21 |
| 2023 | 12 | 15 |
| 2024 | 16 | 17 |
| 2025 | 7 | 7 |
| 2026 | 11 | 10 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Rapid elicitation of broadly neutralizing bovine antibodies to HIV Env25 Aug 2026US 12,715,907 B2International AIDS Vaccine Initiative
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Protein-based purification matrices and methods of using the same28 Jul 2026US 12,692,483 B2Donaldson Company, Inc.
- Immunogenic trimers2 Jun 2026US 12,642,848 B2International AIDS Vaccine Initiative
- Arc-based capsids and uses thereof5 May 2026US 12,617,822 B2Aera Therapeutics, Inc.
- Hiv vaccine24 Sep 2026US 2026/0284176 A1
- Immunogenic trimers17 Sep 2026US 2026/0273042 A1International AIDS Vaccine Initiative
- Recombinant hiv env polypeptides and their use27 Aug 2026US 2026/0250331 A1International AIDS Vaccine Initiative
- Engineered virus-like-particles for targeted capture of membrane proteins16 Jul 2026US 2026/0200991 A1
- Broadly neutralizing antibody-templated divalent immunogen vaccines16 Jul 2026US 2026/0201018 A1University of Hawaii
Most cited
By later US patents
- Monoclonal antibodies to human immunodeficiency virus and uses thereof24US 6,818,392 B2Abbott Laboratories · 2004
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Chloride salt of TAT-NR2B9c14US 10,206,973 B2NoNO Inc. · 2019
- Recombinant HCMV and RHCMV vectors and uses thereof13US 9,982,241 B2Oregon Health & Science University · 2018
- Method of evaluating a patient antibody response to envelope proteins of a virus12US 7,247,439 B1Monogram Biosciences, Inc. · 2007